15.85 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to AUPH. AUPH was compared to 529 industry peers in the Biotechnology industry. AUPH is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. AUPH is growing strongly while it also seems undervalued. This is an interesting combination These ratings would make AUPH suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
AUPH had positive earnings in the past year.
AUPH had a positive operating cash flow in the past year.
AUPH had negative earnings in 4 of the past 5 years.
In the past 5 years AUPH reported 4 times negative operating cash flow.
1.2 Ratios
AUPH's Return On Assets of 14.76% is amongst the best of the industry. AUPH outperforms 95.27% of its industry peers.
AUPH has a better Return On Equity (21.28%) than 96.60% of its industry peers.
AUPH has a better Return On Invested Capital (14.89%) than 95.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.76% | ||
| ROE | 21.28% | ||
| ROIC | 14.89% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AUPH has a better Profit Margin (29.28%) than 95.46% of its industry peers.
With an excellent Operating Margin value of 32.73%, AUPH belongs to the best of the industry, outperforming 96.79% of the companies in the same industry.
The Gross Margin of AUPH (88.93%) is better than 90.74% of its industry peers.
AUPH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.73% | ||
| PM (TTM) | 29.28% | ||
| GM | 88.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so AUPH is creating value.
Compared to 1 year ago, AUPH has less shares outstanding
The number of shares outstanding for AUPH has been increased compared to 5 years ago.
AUPH has a better debt/assets ratio than last year.
2.2 Solvency
AUPH has an Altman-Z score of 7.34. This indicates that AUPH is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of AUPH (7.34) is better than 78.26% of its industry peers.
The Debt to FCF ratio of AUPH is 0.60, which is an excellent value as it means it would take AUPH, only 0.60 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.60, AUPH belongs to the top of the industry, outperforming 94.90% of the companies in the same industry.
A Debt/Equity ratio of 0.15 indicates that AUPH is not too dependend on debt financing.
AUPH has a worse Debt to Equity ratio (0.15) than 65.60% of its industry peers.
Although AUPH does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | 0.6 | ||
| Altman-Z | 7.34 |
ROIC/WACC1.95
WACC7.62%
2.3 Liquidity
AUPH has a Current Ratio of 5.76. This indicates that AUPH is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 5.76, AUPH perfoms like the industry average, outperforming 59.36% of the companies in the same industry.
A Quick Ratio of 5.17 indicates that AUPH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.17, AUPH is in line with its industry, outperforming 58.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.76 | ||
| Quick Ratio | 5.17 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 609.09% over the past year.
Looking at the last year, AUPH shows a very strong growth in Revenue. The Revenue has grown by 20.62%.
The Revenue has been growing by 279.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)609.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130%
Revenue 1Y (TTM)20.62%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%8.41%
3.2 Future
AUPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 70.13% yearly.
The Revenue is expected to grow by 14.93% on average over the next years. This is quite good.
EPS Next Y743.2%
EPS Next 2Y218.19%
EPS Next 3Y124.5%
EPS Next 5Y70.13%
Revenue Next Year18.56%
Revenue Next 2Y16.97%
Revenue Next 3Y15.79%
Revenue Next 5Y14.93%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 28.30, which means the current valuation is very expensive for AUPH.
Compared to the rest of the industry, the Price/Earnings ratio of AUPH indicates a rather cheap valuation: AUPH is cheaper than 92.82% of the companies listed in the same industry.
AUPH is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.43, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 17.39 indicates a rather expensive valuation of AUPH.
94.90% of the companies in the same industry are more expensive than AUPH, based on the Price/Forward Earnings ratio.
AUPH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.66, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.3 | ||
| Fwd PE | 17.39 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AUPH indicates a rather cheap valuation: AUPH is cheaper than 95.09% of the companies listed in the same industry.
AUPH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AUPH is cheaper than 95.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.43 | ||
| EV/EBITDA | 14.39 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AUPH's earnings are expected to grow with 124.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y218.19%
EPS Next 3Y124.5%
5. Dividend
5.1 Amount
No dividends for AUPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:AUPH (12/17/2025, 10:31:43 AM)
15.85
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners50.74%
Inst Owner Change10.72%
Ins Owners1.92%
Ins Owner Change-0.55%
Market Cap2.09B
Revenue(TTM)265.81M
Net Income(TTM)77.84M
Analysts81.54
Price Target17.05 (7.57%)
Short Float %6.91%
Short Ratio5.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.94%
Min EPS beat(2)6.95%
Max EPS beat(2)40.93%
EPS beat(4)4
Avg EPS beat(4)66.5%
Min EPS beat(4)6.95%
Max EPS beat(4)161.28%
EPS beat(8)7
Avg EPS beat(8)112.72%
EPS beat(12)11
Avg EPS beat(12)88.48%
EPS beat(16)14
Avg EPS beat(16)70.43%
Revenue beat(2)2
Avg Revenue beat(2)7.29%
Min Revenue beat(2)6.84%
Max Revenue beat(2)7.75%
Revenue beat(4)2
Avg Revenue beat(4)3.01%
Min Revenue beat(4)-2.09%
Max Revenue beat(4)7.75%
Revenue beat(8)5
Avg Revenue beat(8)4.09%
Revenue beat(12)9
Avg Revenue beat(12)8.29%
Revenue beat(16)13
Avg Revenue beat(16)10.25%
PT rev (1m)42.68%
PT rev (3m)42.68%
EPS NQ rev (1m)8.34%
EPS NQ rev (3m)41.31%
EPS NY rev (1m)14.76%
EPS NY rev (3m)13.59%
Revenue NQ rev (1m)1.33%
Revenue NQ rev (3m)5.32%
Revenue NY rev (1m)3.31%
Revenue NY rev (3m)3.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.3 | ||
| Fwd PE | 17.39 | ||
| P/S | 7.86 | ||
| P/FCF | 17.43 | ||
| P/OCF | 17.4 | ||
| P/B | 5.71 | ||
| P/tB | 5.77 | ||
| EV/EBITDA | 14.39 |
EPS(TTM)0.56
EY3.53%
EPS(NY)0.91
Fwd EY5.75%
FCF(TTM)0.91
FCFY5.74%
OCF(TTM)0.91
OCFY5.75%
SpS2.02
BVpS2.77
TBVpS2.74
PEG (NY)0.04
PEG (5Y)N/A
Graham Number5.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.76% | ||
| ROE | 21.28% | ||
| ROCE | 19.28% | ||
| ROIC | 14.89% | ||
| ROICexc | 67.33% | ||
| ROICexgc | 70.07% | ||
| OM | 32.73% | ||
| PM (TTM) | 29.28% | ||
| GM | 88.93% | ||
| FCFM | 45.1% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
F-Score9
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | 0.6 | ||
| Debt/EBITDA | 0.52 | ||
| Cap/Depr | 1.21% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.83% | ||
| Profit Quality | 154% | ||
| Current Ratio | 5.76 | ||
| Quick Ratio | 5.17 | ||
| Altman-Z | 7.34 |
F-Score9
WACC7.62%
ROIC/WACC1.95
Cap/Depr(3y)6.1%
Cap/Depr(5y)121.69%
Cap/Sales(3y)0.25%
Cap/Sales(5y)3.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)609.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130%
EPS Next Y743.2%
EPS Next 2Y218.19%
EPS Next 3Y124.5%
EPS Next 5Y70.13%
Revenue 1Y (TTM)20.62%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%8.41%
Revenue Next Year18.56%
Revenue Next 2Y16.97%
Revenue Next 3Y15.79%
Revenue Next 5Y14.93%
EBIT growth 1Y448.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8148.86%
EBIT Next 3Y393.34%
EBIT Next 5YN/A
FCF growth 1Y414.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y421.82%
OCF growth 3YN/A
OCF growth 5YN/A
AURINIA PHARMACEUTICALS INC / AUPH FAQ
Can you provide the ChartMill fundamental rating for AURINIA PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 6 / 10 to AUPH.
Can you provide the valuation status for AURINIA PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 7 / 10 to AURINIA PHARMACEUTICALS INC (AUPH). This can be considered as Undervalued.
What is the profitability of AUPH stock?
AURINIA PHARMACEUTICALS INC (AUPH) has a profitability rating of 5 / 10.
What are the PE and PB ratios of AURINIA PHARMACEUTICALS INC (AUPH) stock?
The Price/Earnings (PE) ratio for AURINIA PHARMACEUTICALS INC (AUPH) is 28.3 and the Price/Book (PB) ratio is 5.71.
What is the expected EPS growth for AURINIA PHARMACEUTICALS INC (AUPH) stock?
The Earnings per Share (EPS) of AURINIA PHARMACEUTICALS INC (AUPH) is expected to grow by 743.2% in the next year.